The federal landscape for manufactured kratom products has shifted dramatically. On August 25, 2026, the U.S. Drug Enforcement Administration (DEA) issued a temporary emergency scheduling order placing three highly potent, synthetic kratom-related compounds into Schedule I of the Controlled Substances Act.
The three targeted substances are:
- Mitragynine pseudoindoxyl (frequently referred to as MGPI or pseudoindoxyl)
- MGM-15 (dihydro-7-hydroxymitragynine)
- MGM-16 (9-fluoro-dihydro-7-hydroxymitragynine)
This emergency action makes the unauthorized manufacture, distribution, importation, exportation, and possession of these specific compounds a federal crime.
Why the Federal Government Stepped In
According to the U.S. Department of Justice (DOJ) announcement, these chemicals pose an imminent hazard to public safety. While marketed alongside traditional kratom products, federal agencies like the Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) clarified that these three compounds do not occur naturally in the kratom plant. Instead, they are highly concentrated, manufactured chemical modifications or derivatives of the kratom alkaloid 7-hydroxymitragynine (7-OH).
Scientific evaluations provided by the DEA show that these compounds function as potent mu-opioid receptor agonists with an abuse potential and an analgesic strength that significantly exceeds morphine. The emergency ban was enacted to prevent these synthetic opioids from becoming a wider threat, especially as they began appearing in consumer retail products with labeling that hid their true potency.
The Scope and Legal Impact of the Ban
| Controlled Substance | Alternative Names | New Legal Classification | Effective Date |
|---|---|---|---|
| Mitragynine pseudoindoxyl | MGPI, Pseudo, MP | Schedule I (Temporary) | August 25, 2026 |
| MGM-15 | Dihydro-7-hydroxymitragynine | Schedule I (Temporary) | August 25, 2026 |
| MGM-16 | 9-fluoro-dihydro-7-hydroxymitragynine | Schedule I (Temporary) | August 25, 2026 |
Data Source: Federal Register Temporary Placement Order
The temporary Schedule I status is effective for two years, with a possible one-year extension while the DEA evaluates a permanent scheduling framework. Only researchers and handlers with explicit Schedule I licensing are legally permitted to possess or work with these compounds.
What This Means for the Kratom Industry and Consumers
If you are a consumer or vendor of traditional, plain-leaf kratom, it is important to note the distinction made by regulators: natural botanical kratom and Kratom extracts that don’t contain the above compounds remain legal at the federal level.
The DEA’s emergency order is a targeted strike against synthetic and adulterated products rather than the natural plant itself. However, retailers, distributors, and manufacturers must immediately review their existing inventory. Any consumer products containing added or isolated MGPI, MGM-15, or MGM-16 must be pulled from the market immediately to avoid severe administrative, civil, and criminal sanctions.